The Physiological Effects of Pacing on Catheter Ablation Procedures to Treat Atrial Fibrillation (PEP AF)

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease (CD).


Clinical Study Identifier: s16-00813
ClinicalTrials.gov Identifier: NCT02766712
Principal Investigator: Anthony Aizer
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.